Skip to main content

Core Industry Metrics

As part of our mission to be the industry’s go-to source for market data, we provide and update this repository of core pharmaceutical industry metrics free to interested parties. To download the raw data MS Excel sets, use the links below.

CRO Core Metrics   |   CMO Core Metrics   |   Other Core Industry Metrics

Excel sets last updated: January 2023 with data from Q3, 2022

*IQVIA (Quintiles) total gross revenue has been adjusted to the proportion related to R&D solutions. =0.647
PRA and ICON merged in July, 2021 – data will be combined going forward (Q3, 2021)

*Celltrion removed because financials include innovator drugs and CDMO services.

*Companies included: Viatris, Teva, Sun Pharmaceutical, Aurobindo, Lupin
**Innovator companies and companies with medical device offerings omitted from above rankings.

*Companies included: J&J, Pfizer, Roche, Novartis, Merck & Co., GlaxoSmithKline, Sanofi, AbbVie, Takeda, Shanghai Pharmaceuticals

Top 20 Drug Sales

Source: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales

No.
Drug Name
Active Ingredient
Approval Date
FDA-approved use on approval date*
1
Quviviq
daridorexant
1/7/22
To treat insomnia
2
Cibinqo
abrocitinib
1/14/22
To treat refractory, moderate-to-severe atopic dermatitis
3
Kimmtrak
tebentafusp-tebn
1/25/22
To treat unresectable or metastatic uveal melanoma
4
Vabysmo
faricimab-svoa
1/28/22
To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema
5
Enjaymo
sutimlimab-jome
2/4/22
To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease
6
Pyrukynd
mitapivat
2/17/22
To treat hemolytic anemia in pyruvate kinase deficiency
7
Vonjo
pacritinib
2/28/22
To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets
8
Ztalmy
ganaxolone
3/18/22
To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
9
Opdualag
nivolumab and relatlimab-rmbw
3/18/22
To treat unresectable or metastatic melanoma
10
Pluvicto
lutetium (177Lu) vipivotide tetraxetan
3/23/22
To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
11
Vivjoa
oteseconazole
4/26/22
To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
12
Voquezna
vonoprazan, amoxicillin, and clarithromycin
5/3/22
To treat Helicobacter pylori infection
13
Camzyos
mavacamten
4/28/22
To treat certain classes of obstructive hypertrophic cardiomyopathy
14
Vtama
tapinarof
5/23/22
To treat plaque psoriasis
15
Mounjaro
tirzepatide
5/13/22
To improve blood sugar control in diabetes, in addition to diet and exercise  Press Release
16
Amvuttra
vutrisiran
6/13/22
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
17
Xenpozyme
Olipudase alfa
8/31/22
To treat Acid Sphingomyelinase Deficiency
18
Spevigo
spesolimab-sbzo
9/1/22
To treat generalized pustular psoriasis flares
19
Daxxify
daxibotulinumtoixnA-lanm
9/7/22
To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
20
Sotyktu
deucravacitinib
9/9/22
To treat moderate-to-severe plaque psoriasis
21
Rolvedon
9/9/22
To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
22
Terlivaz
eflapegrastim
9/14/22
To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
23
Elucirem
gadopiclenol
9/21/22
To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
24
Omlonti
oomidenepag isopropyl ophthalmic solution
9/22/22
To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension
25
Relyvrio
sodium phenylbutyrate/taurursodiol
9/29/22
To treat amyotrophic lateral sclerosis (ALS) Press Release
26
Lytgobi
futibatinib
9/30/22
To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
27
Imjudo
tremelimumab
10/21/22
To treat unresectable hepatocellular carcinoma
28
Tecvayli
teclistamab-cqyv
10/25/22
To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy
29
Elahere
mirvetuximab soravtansine-gynx
11/14/22
To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
30
Tzield
teplizumab-mzwv
11/18/22
To delay the onset of stage 3 type 1 diabetes Press Release
31
Rezlidhia
olutasidenib
12/1/22
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
32
Krazati
adagrasib
12/12/22
To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
33
Sunlenca
lenacapavir
12/22/22
To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations Press Release
34
Lunsumio
mosunetuzumab-axgb
12/22/22
To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma
35
Xenoview
hyperpolarized Xe-129
12/22/22
To evaluate pulmonary function and imaging

Core Industry Metrics Updates

Sign up to receive a notification when we update our Core Pharmaceutical Industry Metrics.